Q-omics provides the consensus-scored ZSWIM2 profile across patient tissues and cancer cell-line models. ZSWIM2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZSWIM2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, ZSWIM2 RNA expression shows 9,216 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, BRCA, and PCPG as cancer lineages where ZSWIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSWIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSWIM2 survival associations across molecular data types. ZSWIM2 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSWIM2 RNA expression–survival associations across cancer types. High ZSWIM2 expression shows unfavorable associations in KIRP, KICH, UCEC, THCA and LUAD, but favorable associations in PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZSWIM2 RNA expression.
This table summarizes ZSWIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZSWIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSWIM2 shows lower tumor expression in BRCA, KICH and KIRC and higher tumor expression in THCA. The BRCA box plot shows higher ZSWIM2 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .013).
This table shows molecular features associated with ZSWIM2 in patient tissues and cancer cell lines. In patient samples, ZSWIM2 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSWIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
